Cargando…
Use of Bortezomib in the Treatment of C3 Glomerulonephritis Refractory to Eculizumab and Rituximab
Autores principales: | Hui, Jessica W., Banks, Mindy, Nadasdy, Tibor, Rovin, Brad H., Abbott, Jordan K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7270979/ https://www.ncbi.nlm.nih.gov/pubmed/32518880 http://dx.doi.org/10.1016/j.ekir.2020.03.022 |
Ejemplares similares
-
Membranoproliferative Glomerulonephritis With Changing Immunofluorescence Pattern
por: Satoskar, Anjali A., et al.
Publicado: (2022) -
Long-term Eculizumab Therapy in a Child With Refractory Immune Complex–Mediated Membranoproliferative Glomerulonephritis
por: Chanchlani, Rahul, et al.
Publicado: (2017) -
Subclass Changes in Fibrillary Glomerulonephritis
por: Biederman, Laura E., et al.
Publicado: (2022) -
Rituximab-Induced Remission in Epstein−Barr Virus−Associated Glomerulonephritis
por: Alabdaljabar, Mohamad S., et al.
Publicado: (2020) -
Beneficial Effect of Rituximab in the Treatment of Esophageal Cancer–Associated Pauci-Immune Glomerulonephritis
por: Ameye, Heleen, et al.
Publicado: (2016)